| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/05/2002 | US6344468 Substituted isoindolones and their use as cyclic GMP modulators in medicaments |
| 02/05/2002 | US6344467 Antiasthmatic, antiallergic and immunosuppressant/immunomodulating properties |
| 02/05/2002 | US6344466 Antithrombotic activity, use in inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, anticoagulants |
| 02/05/2002 | US6344465 Inhibitors of IMPDH enzyme |
| 02/05/2002 | US6344462 Heterocyclic compounds as bradykinin antagonists |
| 02/05/2002 | US6344459 Treating cancer, restenosis, atherosclerosis, endometriosis, and psoriasis |
| 02/05/2002 | US6344456 Piperazinone derivatives and their uses |
| 02/05/2002 | US6344455 Treating cancer, atherosclerosis, restenosis, endometriosis, and psoriasis |
| 02/05/2002 | US6344452 Gastrin receptor antagonist, gastrointestinal disorders, etc |
| 02/05/2002 | US6344450 Lactam compounds and their use as inhibitors of serine proteases and method |
| 02/05/2002 | US6344449 Headache and morphine dependence |
| 02/05/2002 | US6344448 Composition for the treatment of hair loss |
| 02/05/2002 | US6344439 Agents for promoting bone formation |
| 02/05/2002 | US6344438 Therapeutic/cosmetic compositions comprising CGRP antagonists for treating the eyes or eyelids |
| 02/05/2002 | US6344437 Medicine drink food and feed having an action of strengthening bone |
| 02/05/2002 | US6344189 Topical administration of a serine protease inhibitor, such as pai-2. |
| 02/05/2002 | CA2150714C Syndecan stimulation of cellular differentiation |
| 02/05/2002 | CA2081330C 3-indolyl thioacetate derivatives |
| 02/05/2002 | CA2078578C Medical use for tachykinin antagonists |
| 02/05/2002 | CA2016521C Fibronectin binding protein as well as its preparation |
| 01/31/2002 | WO2002008449A2 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases |
| 01/31/2002 | WO2002008401A2 Elongase genes and uses thereof |
| 01/31/2002 | WO2002008399A2 Human kinases |
| 01/31/2002 | WO2002008396A2 Human proteases |
| 01/31/2002 | WO2002008292A2 Human monoclonal antibody against hepatitis c virus e2 glycoprotein |
| 01/31/2002 | WO2002008285A2 Il-17 molecules and uses thereof |
| 01/31/2002 | WO2002008284A2 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| 01/31/2002 | WO2002008272A2 High affinity soluble interleukin-18 receptor |
| 01/31/2002 | WO2002008267A2 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/31/2002 | WO2002008256A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | WO2002008255A2 Cell cycle proteins and mitosis-associated molecules |
| 01/31/2002 | WO2002008251A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | WO2002008250A2 Ghrelin antagonists |
| 01/31/2002 | WO2002008244A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | WO2002008232A1 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 01/31/2002 | WO2002008231A2 Biologically active macrolides, compositions, and uses thereof |
| 01/31/2002 | WO2002008226A2 Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors |
| 01/31/2002 | WO2002008223A1 Indole derivatives useful for the treatment of cns disorders |
| 01/31/2002 | WO2002008221A2 Capsaicin receptor ligands |
| 01/31/2002 | WO2002008219A2 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission |
| 01/31/2002 | WO2002008217A2 COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS |
| 01/31/2002 | WO2002008213A1 Colchinol derivatives as angiogenesis inhibitors |
| 01/31/2002 | WO2002008212A1 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide |
| 01/31/2002 | WO2002008209A1 Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators |
| 01/31/2002 | WO2002008208A1 Process for the preparation of optically active thiazolidinone derivatives |
| 01/31/2002 | WO2002008200A2 Arylethene-sulfonamides, their preparation and their use as endothelin antagonists |
| 01/31/2002 | WO2002008198A2 Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | WO2002008189A1 Compounds and inhibitors of phospholipases |
| 01/31/2002 | WO2002008187A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | WO2002008185A1 Pyrrolidine derivatives as metalloprotease inhibitors |
| 01/31/2002 | WO2002008179A1 Aryl sulfonamides as serotonin antagonist for the treatment of obesity |
| 01/31/2002 | WO2002008178A1 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation |
| 01/31/2002 | WO2002007777A1 USE OF THE INTERFERON RECEPTOR 2c POLYPEPTIDE CHAIN TO ENHANCE THE ANTI-GROWTH EFFECTS OF TYPE I INTERFERONS |
| 01/31/2002 | WO2002007773A2 Multi-component biological transport systems |
| 01/31/2002 | WO2002007753A2 Method for treating unstable angina pectoris |
| 01/31/2002 | WO2002007748A2 Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor |
| 01/31/2002 | WO2002007733A2 Method for enhancing bone mineral density gain by administration of raloxifene |
| 01/31/2002 | WO2002007730A1 Alpha v integrin receptor antagonists |
| 01/31/2002 | WO2002007728A1 Hair loss prevention |
| 01/31/2002 | WO2002007727A1 Use of pyridazino(4,5-)indole-1-acetamide derivatives for preparing medicines for treating pathologies related to the dysfunction of peripheral benzodiazepin receptors |
| 01/31/2002 | WO2002007724A1 FREEZE-DRIED PREPARATION OF N-[o-(p-PIVALOYLOXYBENZENESULFONYLAMINO)BENZOYL]GLYCINE MONOSODIUM SALT TETRAHYDRATE AND PROCESS FOR PRODUCING THE SAME |
| 01/31/2002 | WO2002007722A2 Valproic acid and derivatives thereof as histone deacetylase inhibitors |
| 01/31/2002 | WO2002007721A2 Use of cox-2 inhibitors for preventing immunodeficiency |
| 01/31/2002 | WO2002007719A1 Use of estramustine phosphate in the treatment of bone metastasis |
| 01/31/2002 | WO2002007683A1 Antimicotic nail varnish composition |
| 01/31/2002 | WO2002007678A2 Mu-conopeptides |
| 01/31/2002 | WO2002007673A2 Calcilytic compounds |
| 01/31/2002 | WO2002007533A2 Nutritional composition |
| 01/31/2002 | WO2002007516A2 Uses for nad synthetase inhibitors |
| 01/31/2002 | WO2001078580A3 A method combining inducing hypothermia and administering a therapeutic agent |
| 01/31/2002 | WO2001070682A3 Carbocyclic side chain containing metalloprotease inhibitors |
| 01/31/2002 | WO2001070668A3 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 01/31/2002 | WO2001068146A3 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 01/31/2002 | WO2001064870A3 Mutated cyclin g1 protein |
| 01/31/2002 | WO2001062775A3 Novel antiarrhythmic peptides |
| 01/31/2002 | WO2001062341A3 Combination product for the treatment of obesity |
| 01/31/2002 | WO2001061017A3 Modified cytokines for use in cancer therapy |
| 01/31/2002 | WO2001060348A3 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| 01/31/2002 | WO2001054677A3 Ace inhibitor-vasopressin antagonist combinations |
| 01/31/2002 | WO2001049272A3 Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals |
| 01/31/2002 | WO2001044284A3 Chimeric natriuretic peptides |
| 01/31/2002 | WO2001039778A3 Triazinone compounds for treating diseases resulting from infestation with parasitic protozoans |
| 01/31/2002 | WO2001038503A3 Novel human protein kinases and protein kinase-like enzymes |
| 01/31/2002 | WO2001008634A3 Polynucleotide encoding a human serine protease |
| 01/31/2002 | WO2000059941A9 Purposeful movement of human migratory cells away from an agent source |
| 01/31/2002 | US20020013485 Cytotoxic agents comprising taxanes and their therapeutic use |
| 01/31/2002 | US20020013484 Water solubility; prodrug containing polyether oligomer |
| 01/31/2002 | US20020013459 Process for the preparation of macrocyclic metalloprotease inhibitors |
| 01/31/2002 | US20020013372 Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors |
| 01/31/2002 | US20020013370 Methods for identifying and treating resistant tumors |
| 01/31/2002 | US20020013367 For therapy of neoplastic disease |
| 01/31/2002 | US20020013358 Indole derivatives |
| 01/31/2002 | US20020013357 Valdecoxib compositions |
| 01/31/2002 | US20020013354 p38 map kinase inhibitors |
| 01/31/2002 | US20020013353 Blocking of associated non-inactivating sodium channels in retinal ganglion cells in order to limit sodium/calcium exchange in retinal ganglion cells and prevent buildup of calcium level in retinal ganglion cells to a lethal level |
| 01/31/2002 | US20020013352 Novel substituted diamine derivatives useful as motilin antagonists |
| 01/31/2002 | US20020013347 Tri-aryl-substituted-ethane PDE4 inhibitors |
| 01/31/2002 | US20020013341 For therapy of acute infection, acute phase response, age related macular degeneration, alcoholism, anorexia, asthma, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrtate deposition |
| 01/31/2002 | US20020013339 Nutritional and therapeutic uses of 3-hydroxyalkanoate oligomers |
| 01/31/2002 | US20020013336 Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases |